Rubraca (rucaparib), Clovis Oncology‘s oral PARP inhibitor, shrank tumors in 44% of metastatic hormone-resistant prostate cancer (mCRPC) patients with BRCA mutations included in the Phase 2 TRITON2 clinical trial. The treatment, which is already approved for ovarian cancer, also reduced PSA levels — a biomarker of prostate cancer — in 51.1% of patients with BRCA mutations.
http://feedproxy.google.com/~r/GodAndProstate/~3/HcU0Zzpb_7U/?utm_source=feedburner&utm_medium=email
Yet Another Prostate Cancer Blog 
I hate to be the one to tell you, but the black on black text is back.
I just don’t know what WordPress’ problem is. I’m going to ignore it this time.
It is interesting.